About: Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $5.85 (-3.47%)
CMND NASDAQ Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc. Common Shares share price
Atividade de preço de CMND
Último preço
$ 5,850
Variação (24h)
-0,21 USD (3,47%)
Volume
4.30K
Volume (média 4 sem.)
-
Abertura
$ 6,15
Variação do dia
$ 5,85 - $ 6,17
Fechamento anterior
$ 6,06
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
CMND price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals